Somayeh Abolhasani1,2, Alireza Khabbazi3, Foroogh Hosseini4, Shiva Gholizadeh-Ghaleh Aziz1, Shahriar Alipour1,2. 1. Department of Biochemistry, Faculty of Medicine, Urmia University of Medical Sciences, Urmia 5756115111, Iran. 2. Student Research Committee, Urmia University of Medical Sciences, Urmia 5756115111, Iran. 3. Connective Tissue Diseases Research Center, Tabriz University of Medical Science, Tabriz 5166614766, Iran. 4. Department of Biochemistry, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz 5166614766, Iran.
Abstract
AIM: To investigate effects of anti-TNF biologic drugs on uveitis severity (comparing visual acuity logMAR levels) in Behçet patients. METHODS: Three databases PubMed, Scopus, and the Web of Science were searched for qualified papers focusing on the anti-TNF-α factors treatment in Behçet's disease (BD)-associated uveitis. Studies that were designed pre and post anti-TNF drug treatment, were selected. After determining the search strategy for this study, the relevant data were extracted. RESULTS: The initial search was performed in the target databases and a total of about 1458 articles were found. Fifteen articles were selected for systematic review and only 12 of them had inclusion criteria for Meta-analysis (with visual acuity data). The mean dose of prednisolone before and after biological treatments was reported in 5 studies (28.56 and 7.56 mg/kg, respectively). Also, the preliminary results indicate a significant reduction in visual acuity logMAR levels (MD=-1.5 IU/L, 95%CI: -2.1, -0.01). CONCLUSION: Biological drugs significantly reduce the dose of prednisolone and affect visual acuity values. International Journal of Ophthalmology Press.
AIM: To investigate effects of anti-TNF biologic drugs on uveitis severity (comparing visual acuity logMAR levels) in Behçet patients. METHODS: Three databases PubMed, Scopus, and the Web of Science were searched for qualified papers focusing on the anti-TNF-α factors treatment in Behçet's disease (BD)-associated uveitis. Studies that were designed pre and post anti-TNF drug treatment, were selected. After determining the search strategy for this study, the relevant data were extracted. RESULTS: The initial search was performed in the target databases and a total of about 1458 articles were found. Fifteen articles were selected for systematic review and only 12 of them had inclusion criteria for Meta-analysis (with visual acuity data). The mean dose of prednisolone before and after biological treatments was reported in 5 studies (28.56 and 7.56 mg/kg, respectively). Also, the preliminary results indicate a significant reduction in visual acuity logMAR levels (MD=-1.5 IU/L, 95%CI: -2.1, -0.01). CONCLUSION: Biological drugs significantly reduce the dose of prednisolone and affect visual acuity values. International Journal of Ophthalmology Press.
Authors: Belén Atienza-Mateo; José Luis Martín-Varillas; Vanesa Calvo-Río; Rosalía Demetrio-Pablo; Emma Beltrán; Juan Sánchez-Bursón; Marina Mesquida; Alfredo Adan; María Victoria Hernández; Marisa Hernández-Garfella; Elia Valls-Pascual; Lucía Martínez-Costa; Agustí Sellas-Fernández; Miguel Cordero-Coma; Manuel Díaz-Llopis; Roberto Gallego; José L García-Serrano; Norberto Ortego-Centeno; José M Herreras; Alejandro Fonollosa; Ángel M Garcia-Aparicio; Olga Maíz-Alonso; Ana Blanco; Ignacio Torre-Salaberri; Cruz Fernandez-Espartero; Vega Jovaní; Diana Peiteado; Esperanza Pato; Juan Cruz; Carlos Férnandez-Cid; Elena Aurrecoechea; Miriam García-Arias; Santos Castañeda; Miguel A Caracuel-Ruiz; Carlos A Montilla-Morales; Antonio Atanes-Sandoval; Félix Francisco; Santos Insua; Senen González-Suárez; Amalia Sanchez-Andrade; Fernando Gamero; Luis F Linares Ferrando; F Romero-Bueno; A Javier García-González; Raquel Almodóvar González; Enrique Minguez Muro; Carmen Carrasco-Cubero; Alejandro Olive; Águeda Prior; Julio Vázquez; Oscar Ruiz-Moreno; Fernando Jiménez-Zorzo; Javier Manero; Santiago Muñoz Fernandez; Cristina Fernández-Carballido; Esteban Rubio-Romero; Fred Antón Pages; Francisco J Toyos-Sáenz de Miera; Myriam Gandia Martinez; David Díaz-Valle; Francisco J López Longo; Joan M Nolla; Enrique Raya Álvarez; Marcelino Revenga Martínez; Julio José González-López; Paz Rodríguez-Cundin; José L Hernández; Miguel A González-Gay; Ricardo Blanco Journal: Arthritis Rheumatol Date: 2019-10-21 Impact factor: 10.995